Compare GKOS & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | FMS |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.5B |
| IPO Year | 2015 | 2005 |
| Metric | GKOS | FMS |
|---|---|---|
| Price | $180.54 | $22.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 7 |
| Target Price | ★ $199.31 | $23.72 |
| AVG Volume (30 Days) | 979.8K | ★ 1.2M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 2.68% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $36.30 | N/A |
| Revenue Next Year | $23.25 | $3.49 |
| P/E Ratio | ★ N/A | $15.62 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $80.91 | $20.02 |
| 52 Week High | $191.62 | $26.95 |
| Indicator | GKOS | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 54.76 |
| Support Level | $175.04 | $22.37 |
| Resistance Level | $184.68 | $22.59 |
| Average True Range (ATR) | 6.45 | 0.41 |
| MACD | 1.90 | 0.16 |
| Stochastic Oscillator | 80.18 | 78.60 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.